The FDA Peptide Advisory Meeting (July 2026): What It Means for the Compounding Industry

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) will meet to review seven peptide molecules for potential Category 1 placement — which would allow their compounding under enforcement discretion. BPC-157, a popular recovery peptide, is among them.

GLP-1 medications are NOT included in this review. But the meeting matters for GLP-1 compounding patients because it signals how the FDA is approaching the broader compounding landscape — and the two markets are deeply interconnected.

What's Being Reviewed

The FDA removed 12 peptides from Category 2 in April 2026. Now the PCAC will evaluate whether BPC-157 and six other compounds should move to Category 1, which would provide a clearer legal pathway for 503A and 503B compounding.

Many of the pharmacies that compound GLP-1 medications also compound peptides like BPC-157, TB-500, Sermorelin, and others. Decisions at this meeting affect their business models, compliance posture, and the resources they have available for GLP-1 operations.

Why This Matters for GLP-1 Patients

Same pharmacies, connected fates: If the PCAC grants Category 1 status to popular peptides, it stabilizes the business model of compounding pharmacies that also produce GLP-1s. If it doesn't, financial pressure on these pharmacies intensifies.

Regulatory signals: The FDA's approach to peptide compounding tells us how they're thinking about compounding broadly. A permissive stance on peptides might signal tolerance for continued 503A GLP-1 compounding. An aggressive stance suggests the agency is tightening across the board.

Stacking protocols: Many patients combine GLP-1 therapy with peptides like Sermorelin (for GH support) or BPC-157 (for gut healing during GI side effects). The regulatory status of these add-ons directly affects treatment options.

What to Watch For

• BPC-157 decision: The most commercially significant peptide in the review. Category 1 would stabilize compounding pharmacy revenue.
• Safety language: How the PCAC characterizes compounding safety risks will influence broader FDA posture
• 503A vs. 503B treatment: Whether the committee differentiates between pharmacy types in their recommendations

We'll update this article after the July 23–24 meeting with the committee's recommendations.